Z Prime Therapeutics
PrivateCompany Overview
Z Prime Therapeutics is a drug discovery company that develops precision oncology therapeutics using synthetic lethality to target genetically defined tumors.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
precision oncologysmall molecule therapeuticssynthetic lethalitydrug discoverytechbiocomputational biologyoncology pipelinegenetically defined cancertargeted therapybiotech startupundruggable targetsai-augmented drug discovery
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Z Prime Therapeutics Comparables
Compare Z Prime Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Delphia Therapeutics | 84% | |
| Eisbach Bio GmbH | 82% | |
| Evariste | 81% | |
Z Prime Therapeutics Funding Rounds
Historical fundraising activity
Z Prime Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Boutique Venture Partners | Pre Seed |
Z Prime Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Z Prime Therapeutics's valuation, stock price, and market status.
Firmographic Details
HeadquartersMountain View, California
Year Founded2025
Last Funding—
See something wrong or outdated?